The narrow therapeutic window for stroke intervention has long frustrated clinicians and devastated families who arrive at hospitals just hours too late for standard care. This limitation may be shifting as evidence emerges for extending treatment timelines in carefully selected patients with salvageable brain tissue. The JAMA study evaluated tenecteplase, a modified tissue plasminogen activator, in acute ischemic stroke patients with non-large vessel occlusions who presented between 4.5 and 24 hours after symptom onset. The research specifically targeted patients with imaging evidence of penumbral tissue—brain regions that remain viable but at risk. This represents a significant departure from the traditional approach of treating all stroke patients within the same rigid timeframe regardless of individual tissue viability. The findings contribute to a growing body of evidence suggesting that personalized stroke care based on imaging biomarkers rather than time alone may revolutionize treatment protocols. However, this approach requires sophisticated imaging capabilities and neurological expertise that may not be universally available, potentially creating disparities in care access. The focus on non-large vessel occlusions is particularly relevant since these represent the majority of ischemic strokes, yet have received less attention than dramatic large vessel cases that dominate headlines. While promising, single-study findings in stroke research require cautious interpretation given the heterogeneous nature of cerebrovascular disease and the complex interplay between timing, tissue viability, and patient factors that influence outcomes.